Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Divestments (2020 - 2021)

Myriad Genetics (MYGN) has disclosed Divestments for 2 consecutive years, with $379.1 million as the latest value for Q3 2021.

  • Quarterly Divestments rose 1679.81% to $379.1 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $379.1 million through Dec 2024, changed 0.0% year-over-year, with the annual reading at $8.8 million for FY2024, N/A changed from the prior year.
  • Divestments for Q3 2021 was $379.1 million at Myriad Genetics, up from $21.3 million in the prior quarter.
  • The five-year high for Divestments was $379.1 million in Q3 2021, with the low at -$21.3 million in Q2 2020.